A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...

The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to ...

Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...

In 2025, the market was valued at $2.7 billion, projected to reach $2.92 billion in 2026, with a CAGR of 8.1%. This ...

At Novocure, we are very proud of our ongoing commitment and dedication to improving the lives of people with brain cancer. Our patients, their families and caregivers are at the heart of everything ...

A high-school student who experienced nausea was later diagnosed with an aggressive and deadly brain tumor. The boy, who has only been identified by his first name, Tom, was told by doctors that he ...

Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...